Charlene Marshall was diagnosed with idiopathic pulmonary fibrosis (IPF) in 2016. The condition unfortunately has no cure. However, Charlene explains how grateful she is for the scientists that are investigating…
Welcome to Study of the Week from Patient Worthy. In this segment, we select a study we posted about from the previous week that we think is of particular interest…
According to a news release from pharmaceutical company Citryll, the first healthy volunteer was dosed with CIT-013 in a Phase 1 clinical trial. Altogether, the drug is being developed to…
In the Phase 3 PANTHER clinical trial, also known as the Pevonedistat-3001 study, researchers were evaluating pevonedistat in conjunction with azacitidine for patients with acute myeloid leukemia (AML), myelodysplastic syndromes…
782 words (source) vs. 472 words (mine) - 1% match Some rare diseases or rare cancers are exceedingly difficult to treat. For example, for patients with early-stage cutaneous T-cell lymphoma…
327 words (source) vs. 385 words (mine) - 6% match Looking into the future, new forms of medical technology offer the opportunity to improve patient outcomes like never before. For…
September 7, 2021 will be recognized as World Duchenne Awareness Day. This day will be set aside in recognition of awareness surrounding Duchenne muscular dystrophy, a rare and debilitating genetic…
Nivolumab has recently received an additional indication for the treatment of urothelial carcinoma with a high risk for recurrence following radical resection, a form of bladder cancer. This decision came…
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
